bioMerieux puts Novel's TB (Tuberculosis) test on 12-month trial
This article was originally published in Clinica
Executive Summary
French firm bioMerieux is funding a 12-month trial to test the efficacy of Novel Diagnostics' antibody technology for TB detection, PlasmAcute. A product could be commercially available next year if the collaboration proves successful, Novel Diagnostics told Clinica.